Developer docs
API playgroundTry for free, no card

Search company profiles

Mika

Full company profile

uuid000282x

Namestring
Mika
Legal namestring
Fosanis
Websiteurl
mikahealth.com
Company typeenum
Private
Founded yearint
2017
Descriptiontext

Mika is an app-based digital therapeutics platform developed by Berlin-based digital health company Fosanis (legal entity). Founded in 2017, the platform is designed to support cancer patients throughout their therapy journey through AI-powered digital interventions. The company positions its core technology as domain-specialized AI applied to oncology, differentiating it from general wellness apps by focusing exclusively on the cancer therapy experience. Mika distributes its product primarily via a direct-to-consumer mobile app, with a parallel healthcare provider integration channel for clinical workflow embedding. The business model is structured around subscription/recurring revenue, though pricing is not publicly disclosed; reimbursement through healthcare systems is a potential monetization pathway aligned with the German DiGA framework. Geographic operations are based in Germany with a publicly stated intention to expand into the UK healthcare market. Mika has raised over €10 million across funding stages, including a May 2022 Series A led by healthcare-specialist investors including Debiopharm Innovation Fund, alongside impact investors Ship2B Ventures and Equity Pitcher, with earlier backing from Ananda Impact Ventures, IBB Ventures, and Plug and Play Insurtech. Strategic priorities articulated in conjunction with funding include international expansion, research center collaborations for clinical validation, and broadening the platform's clinical credibility. The company is co-led by founders Gandolf Finke and Jan Raue as managing directors, with a headcount in the 11-50 range.

Short descriptiontext

Mika (developed by Berlin-based Fosanis) is an AI-powered app-based digital therapeutics platform that supports cancer patients throughout their therapy journey, distributed primarily via a mobile app across Germany with planned UK expansion.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersBerlin, Germany
HQ citystring
Berlin
HQ countrystring
Germany
HQ regionstring
Europe
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
digital therapeutics platform, cancer therapy support, oncology digital health, AI patient engagement, mobile health app
Industry2 codes
1Oncology Remote Symptom Monitoring & Care Navigation
CodeHLALAFADPrimaryYes
2Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs)
CodeHLALAFAFPrimaryNo
NAICS code1 code
  • Computer Systems Design and Related Services54151
SIC code1 code
  • Services-Health Services8000
Product category
Digital Therapeutics
Social media profiles1 record
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model1 record
1Digital Therapeutics Platform
TypeSubscription Recurring
Description

Mika operates as an app-based digital therapeutics platform generating revenue through its cancer support technology. As a Series A funded company, the business model appears to be focused on healthcare market expansion with potential reimbursement through healthcare systems or direct patient payments.

prnewswire.co.uk
Marketing channels3 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components4 values
Technology or R&D, Personnel, Marketing or Sales, Operations
GTM typeB2C
B2C
Offering typeSoftware
Software
Core offering1 text field

Mika is an AI-powered mobile digital therapeutics platform that supports cancer patients throughout their therapy journey. Delivered as an app-based product by Fosanis GmbH, it provides personalized digital therapeutic interventions and continuous patient engagement between clinical visits. The offering is focused exclusively on oncology and serves as the company's single unified product.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • Over €10 million raised to support international expansion and UK market entry
Product overview1 text field

Mika is a single unified app-based digital therapeutics platform developed by Fosanis, a Berlin-based digital health company. The platform provides AI-powered cancer therapy support to patients and serves as the company's core product offering.

Product and service1 record
1Mika
CategoryDigital Therapeutics
Description

AI-powered app-based digital therapeutics platform that supports cancer patients throughout their therapy journey, delivering personalized digital therapeutic interventions via a mobile app. Built for individual cancer patients and oncology healthcare providers seeking continuous, between-visit support.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
1International Research Centers
Strategic tierMinorTypeStrategic or Co-development PartnerAnnounced on2022-05-09
Description

Mika plans to foster partnerships with international research centers to support clinical validation and evidence generation. These research partnerships aim to strengthen the platform's clinical credibility and enable data-driven improvements to the AI-powered cancer therapy support.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Market position
Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles2 records

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds7 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors10 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Mika

Digital Therapeuticsmikahealth.com

Mika (developed by Berlin-based Fosanis) is an AI-powered app-based digital therapeutics platform that supports cancer patients throughout their therapy journey, distributed primarily via a mobile app across Germany with planned UK expansion.

What Mika does

Mika is an app-based digital therapeutics platform developed by Berlin-based digital health company Fosanis (legal entity). Founded in 2017, the platform is designed to support cancer patients throughout their therapy journey through AI-powered digital interventions. The company positions its core technology as domain-specialized AI applied to oncology, differentiating it from general wellness apps by focusing exclusively on the cancer therapy experience. Mika distributes its product primarily via a direct-to-consumer mobile app, with a parallel healthcare provider integration channel for clinical workflow embedding. The business model is structured around subscription/recurring revenue, though pricing is not publicly disclosed; reimbursement through healthcare systems is a potential monetization pathway aligned with the German DiGA framework. Geographic operations are based in Germany with a publicly stated intention to expand into the UK healthcare market. Mika has raised over €10 million across funding stages, including a May 2022 Series A led by healthcare-specialist investors including Debiopharm Innovation Fund, alongside impact investors Ship2B Ventures and Equity Pitcher, with earlier backing from Ananda Impact Ventures, IBB Ventures, and Plug and Play Insurtech. Strategic priorities articulated in conjunction with funding include international expansion, research center collaborations for clinical validation, and broadening the platform's clinical credibility. The company is co-led by founders Gandolf Finke and Jan Raue as managing directors, with a headcount in the 11-50 range.

Mika firmographics

Firmographics
Name
Mika
Legal name
Fosanis
Website
https://mikahealth.com
Company type
Private
Founded year
2017
Operating status
Operating
Headcount range
11–50 employees
Short description
Mika (developed by Berlin-based Fosanis) is an AI-powered app-based digital therapeutics platform that supports cancer patients throughout their therapy journey, distributed primarily via a mobile app across Germany with planned UK expansion.
Ownership category
akta.pro rank

Mika industry classification

Industry
Product category
Digital Therapeutics
NAICS
Computer Systems Design and Related Services (54151)
SIC
Services-Health Services (8000)
akta.pro primary industry
Oncology Remote Symptom Monitoring & Care Navigation (HLALAFAD)
akta.pro secondary industry
Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs) (HLALAFAF)

Keywords

  • Digital therapeutics platform
  • Cancer therapy support
  • Oncology digital health
  • AI patient engagement
  • Mobile health app

Where Mika is headquartered

Location

Headquarters

HQ city
Berlin
HQ country
Germany
HQ region
Europe

Offices1 record

Markets served

Mika business model

Business model
GTM type
B2C
Offering type
Software
Cost components
Technology or R&D, Personnel, Marketing or Sales, Operations

Revenue model

  1. Digital Therapeutics Platform: Mika operates as an app-based digital therapeutics platform generating revenue through its cancer support technology. As a Series A funded company, the business model appears to be focused on healthcare market expansion with potential reimbursement through healthcare systems or direct patient payments.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels3 records

Mika product offering

Product offering

Core offering

Mika is an AI-powered mobile digital therapeutics platform that supports cancer patients throughout their therapy journey. Delivered as an app-based product by Fosanis GmbH, it provides personalized digital therapeutic interventions and continuous patient engagement between clinical visits. The offering is focused exclusively on oncology and serves as the company's single unified product.

Product overview

Mika is a single unified app-based digital therapeutics platform developed by Fosanis, a Berlin-based digital health company. The platform provides AI-powered cancer therapy support to patients and serves as the company's core product offering.

Differentiator

Problem solved

Functional benefit

Products and services

  • Mika AI-powered app-based digital therapeutics platform that supports cancer patients throughout their therapy journey, delivering personalized digital therapeutic interventions via a mobile app. Built for individual cancer patients and oncology healthcare providers seeking continuous, between-visit support.

Quantifiable outcome

  • Over €10 million raised to support international expansion and UK market entry

Companies that use Mika

Customer profile

Segments1 record

Ideal customer profiles2 records

Mika technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

Mika partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • International Research CentersminorStrategic or Co-development Partner · 9 May 2022Mika plans to foster partnerships with international research centers to support clinical validation and evidence generation. These research partnerships aim to strengthen the platform's clinical credibility and enable data-driven improvements to the AI-powered cancer therapy support.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

Mika competitors and assessment

Company assessment

Market position

Competitive moat4 records

Key risks6 records

Key highlights6 records

Customer concentration

Mika social profiles

Digital presence

Mika financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Mika leadership team

Management profile

Number of profiles

Profiles2 records

Mika funding detail

Funding detail

Funding overview

Funding rounds7 records

Investors10 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Mika M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Mika

What does Mika do?

Mika is an AI-powered mobile digital therapeutics platform that supports cancer patients throughout their therapy journey. Delivered as an app-based product by Fosanis GmbH, it provides personalized digital therapeutic interventions and continuous patient engagement between clinical visits. The offering is focused exclusively on oncology and serves as the company's single unified product.

Is Mika a public or private company?

Mika is a private company. It is classified as venture growth investor backed and is currently operating.

When was Mika founded?

Mika was founded in 2017. It employs 11 to 50 people.

Where is Mika based?

Mika is headquartered in Berlin, Germany, in the Europe region.

How does Mika make money?

One revenue line is on record: digital Therapeutics Platform.

Does Mika have an API?

No public API is recorded for Mika.

What industry is Mika in?

Mika's product category is Digital Therapeutics. Its primary akta.pro industry code is HLALAFAD, Oncology Remote Symptom Monitoring & Care Navigation, with a secondary code of HLALAFAF, Medication Adherence, Digital Therapeutics & Remote Coaching (condition-specific programs). Its NAICS code is 54151 and its SIC code is 8000.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Startups MagazineDigital cancer support platform Mika is launched in the UKDigital oncology platform Mika has launched in the UK on Android and iOS, expanding its presence as a leading digital therapeutic for cancer patients. The AI-powered app provides personalized support to help address treatment delays and emotional distress within the NHS system. This launch marks the company's international expansion from Germany into new markets.GlobeNewswireMika Health Collaborates with AstraZeneca and Daiichi Sankyo to Deliver AI-Enabled Mobile Support to Women Undergoing Breast Cancer TreatmentMika Health, AstraZeneca, and Daiichi Sankyo announced the UNITE initiative to provide AI-enabled mobile support to women undergoing breast cancer treatment. The program, running in Switzerland since April 2024, will expand to French and Italian-speaking regions. Mika Health has already supported over 100,000 cancer patients in Germany and Great Britain.WebcapitalriesgoShip2B Ventures invierte en la plataforma alemana MikaShip2B Ventures participated in a 10 million euro funding round for Fosanis, the developer of the digital therapy platform Mika, which was led by Swiss firm Debiopharm. The investment aims to expand Mika's international reach and scale its oncology-focused digital therapeutic services beyond Germany. This transaction adds Mika to Ship2B Ventures' portfolio of impact startups supported by the BSocial Impact Fund.Tech.euMeet Mika: Berlin-based digital companion during cancer therapy raises €10 millionBerlin-based health tech startup Fosanis has raised over €10 million in funding for its AI-powered platform Mika, which supports cancer patients during their therapy. The funding will facilitate its entry into the U.K. healthcare ecosystem and potential partnerships with international cancer research centers to study the impact of digital interventions. Fosanis, founded in 2017, aims to enhance patient empowerment and therapy management for those affected by cancer.SpinLab10 promising E-health Startups from GermanyA blog article showcases ten promising German e-health startups, highlighting their digital solutions for telemedicine, mental health, and chronic disease management. These companies have secured significant funding, such as MedKitDoc's €1.7 million round and Kenbi's €7 million seed investment, while some like aidhere and Mika have achieved regulatory approvals for digital health applications.FinSMEsMika Raises Seven Figure Financing RoundMika, a Berlin-based digital health startup, raised a seven-figure financing round from Ananda Impact Ventures and VC Fonds Technologie Berlin. The funds will support clinical studies and further development of its interactive digital companion app for cancer patients. The app, co-developed with Charité and University Hospital Leipzig, provides treatment information, nutritional advice, and a patient diary.ArtistikrezoFanny Ardant dans le clip de Mika Elle Me DitThe article reports that French actress Fanny Ardant appears in a music video by Mika for the song "Elle Me Dit." No additional details or implications are provided within the article.